{"schema_version":"secwatch.filing_event.v1","accession":"0001576280-24-000108","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.044486+00:00","generated_at":"2026-06-02T05:57:17.792923+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Guardant Health Q1 revenue up 31% to $168.5M; raises 2024 revenue guidance to $675-685M","bullets":["Revenue $168.5M (+31% YoY); net loss narrowed to $115M ($0.94 loss per share) from $133.5M.","Precision oncology revenue $156.2M (+38%); clinical tests +20%, biopharma tests +37%.","2024 revenue guidance raised to $675-685M (prior $655-670M); FCF guidance improved to $(275)-$(285)M.","Non-GAAP gross margin ex-screening guided to 61%-63% (prior 60%-62%).","ECLIPSE published in NEJM; FDA Advisory Committee on May 23; Shield IVD launch expected post-approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001576280-24-000108","json":"https://secwatch.observer/filing/0001576280-24-000108.json","markdown":"https://secwatch.observer/filing/0001576280-24-000108.md","text":"https://secwatch.observer/filing/0001576280-24-000108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000157628024000108/0001576280-24-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000157628024000108/gh-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:57:17.792923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e337a5977d9195ec683b79f5acfeff9e4c3d1231","claim":"Guardant Health, Inc. reported full year 2024 results: revenue $675 to $685 million. Guidance raised.","evidence_excerpt":"Guardant Health now expects full year 2024 revenue excluding screening to be in the range of $675 to $685 million, representing growth of 20% to 21% compared to full year 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000157628024000108/0001576280-24-000108-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"$675 to $685 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"ea02a3b0a5dd44804c01b1f0959e0a6cff10c9af","claim":"Guardant Health, Inc. reported the quarter ended March 31, 2024 results: revenue $168.5 million, net income $115.0 million, EPS $0.94.","evidence_excerpt":"Revenue was $168.5 million for the first quarter of 2024, a 31% increase from $128.7 million for the corresponding prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000157628024000108/0001576280-24-000108-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$168.5 million"},{"label":"Net income","value":"$115.0 million"},{"label":"EPS","value":"$0.94"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}